Skip to main content

Peer Review reports

From: A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1 - or BRCA2 -mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

Original Submission
27 Oct 2015 Submitted Original manuscript
17 Mar 2016 Author responded Author comments - Philip C Schouten
1 Feb 2016 Reviewed Reviewer Report - Steven Isakoff
Resubmission - Version 2
17 Mar 2016 Submitted Manuscript version 2
31 May 2016 Author responded Author comments - Philip C Schouten
13 May 2016 Reviewed Reviewer Report - Steven Isakoff
Resubmission - Version 3
31 May 2016 Submitted Manuscript version 3
Publishing
2 Jun 2016 Editorially accepted
21 Jun 2016 Article published 10.1186/s13063-016-1423-0

You can find further information about peer review here.

Back to article page